Emerging therapeutic strategies for asthma management.
OBJECTIVE
The describe the mechanisms of action of and clinical experience to date with novel asthma drug therapies.


METHODS
This article is based, in part, on a presentation given by Eli O. Meltzer, MD, at a symposium entitled. New Frontiers in Asthma Management: Biotechnology for Optimal Therapeutic and Economic Outcomes. at the Academy of Managed Care Pharmacy's 15th Annual Meeting and Showcase in Minneapolis, Minnesota, on April 10, 2003.


CONCLUSIONS
Various elements of the pathophysiologic processes involved in allergic asthma, including type 2 helper T lymphocytes, cytokines, and immunoglobulin E (IgE), have been the targets of new drug research. Clinical experience with omalizumab, a humanized anti-IgE monoclonal antibody, is promising.
Sullivan
Sean D
SD
Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, 1959 NE Pacific Ave., Box 357630, Seattle, WA 98195, USA. sdsull@u.washington.edu
Meltzer
Eli O
EO
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069444:Omalizumab; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D000276:Adjuvants, Immunologic; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007166:Immunosuppressive Agents; D010726:Phosphodiesterase Inhibitors; D000069444:Omalizumab